Lexeo Therapeutics’ (LXEO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a research note released on Wednesday,Benzinga reports. They currently have a $23.00 price target on the stock. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

Several other research analysts have also recently weighed in on the company. Leerink Partners lowered their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday, March 24th. Royal Bank of Canada cut their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Chardan Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $22.80.

Lexeo Therapeutics Stock Down 0.2 %

LXEO stock opened at $4.10 on Wednesday. The stock has a market capitalization of $135.57 million, a P/E ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a 52 week low of $2.32 and a 52 week high of $19.50. The firm has a 50-day simple moving average of $4.05 and a 200-day simple moving average of $6.58. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09. Equities analysts forecast that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently modified their holdings of the company. Allostery Investments LP acquired a new position in Lexeo Therapeutics during the 4th quarter worth $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $46,000. BNP Paribas Financial Markets increased its holdings in Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Lexeo Therapeutics during the 4th quarter worth about $69,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter worth about $72,000. 60.67% of the stock is owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.